1 / 44

Chlamydia and Chlamydophila (Chlamydia)

Chlamydia and Chlamydophila (Chlamydia). Family: Chlamydiaceae. Genus: Chlamydia C. trachomatis - Urogenital infections, trachoma, conjunctivitis, pneumonia and lymphogranuloma venerium (LGV) Genus: Chlamydophila C. psittaci - Pneumonia (psittacosis)

pravat
Download Presentation

Chlamydia and Chlamydophila (Chlamydia)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chlamydia and Chlamydophila (Chlamydia)

  2. Family: Chlamydiaceae • Genus: Chlamydia • C. trachomatis - Urogenital infections, trachoma, conjunctivitis, pneumonia and lymphogranuloma venerium (LGV) • Genus: Chlamydophila • C. psittaci - Pneumonia (psittacosis) • C. pneumoniae - Bronchitis, sinusitis, pneumonia and possibly atherosclerosis Note: New taxonomy, previously three species in one genus - Chlamydia

  3. Chlamydiaceae- Microbiology • Small obligate intracellular parasites • Contain DNA, RNA and ribosomes (so not viruses) • Inner and outer membrane (like Gram - bacteria) • Lipopolysacchride (LPS) but no peptidoglycan • Cell wall not well characterized • LPS has weak endotoxin activity • Energy parasites • Can’t make ATP

  4. Physiology and Structure • Elementary bodies (EB) • Small (0.3 - 0.4 µm) • Extracellular form • Rigid outer membrane • Major outer membrane protein (MOMP) unique to species and variations result in serovars • Disulfide linked proteins (OMP2), highly conserved in family, gives stability • Resistant to harsh conditions (spore-like) • Non-replicating, non-metabolically active form • Infectious form • Bind to columnar epithelial cells (and macrophages in LGV)

  5. Physiology and Structure • Reticulate bodies (RB) • Larger (0.8 - 1 µm) • Intracellular form • Fragile membrane • Fewer disulfide bonds (missing OMP2) • Metabolically active form • Replicating form • Non-infectious

  6. Developmental Cycle of Chlamydia • EB bind to host cells • Epithelial cells • Macrophage (LGV) • Internalization • Endocytosis • Phagocytosis • Inhibition of phagosome-lysosome fusion (if EB outer membrane intact) • Reorganization into RB • Breakdown of disulfide bonds • Growth of RB (binary fission)

  7. Developmental Cycle of Chlamydia • Reorganization into EB • Inclusion bodies (one way to distinguish between species) • Release of EB • Lysis -C. psittaci • Extrusion - C. trachomatis and C. pneumoniae

  8. Chlamydia trachomatis • Trachoma • Inclusion conjunctivitis • Infant pneumonia • Ocular lymphogranuloma venerium • Urogenital infections • Reactive arthritis (Reiter’s syndrome) • Lymphogranuloma venerium

  9. C. trachomatis • Biovars - biological variants • Trachoma • LGV • Mouse pneumonitis (mouse model of disease) • Serovars - serological variants • Different Major outer membrane proteins • A through L

  10. C. trachomatis - Serovars and associated disease Serovars Diseases A, B, Ba, C Trachoma (trachoma biovar) D - K Urogenital tract disease (trachoma biovar) L1, L2, L2a, L2b, L3 Lymphogranuloma venereum (LGV biovar)

  11. C. trachomatis-Pathogenesis and Immunity • Infects nonciliated columnar, cuboidal, and transitional epithelial cells (and macrophages in LGV) • Down regulation of Class I MHC • Infiltration of PMNs and lymphocytes • Lymphoid follicle formation • Fibrosis • Disease results from destruction of cells and host immune response • No long lasting immunity; reinfection results in inflammatory response and tissue damage

  12. C. trachomatis - Epidemiology • Ocular infections - Biovar: trachoma • Worldwide • Poverty and overcrowding • Endemic in Africa, Middle East, India, SE Asia • United States - American Indians • Infection of children • Transmission: droplets, hands, contaminated clothing, flies, contaminated birth canal • Damage to eyes is not seen immediately

  13. C. trachomatis - Epidemiology • Genital tract infections • Biovar: trachoma • Most common STD in US • 2006: USA = 1,030,911; SC = 22,351 • 2007: USA = 1,025208; SC = 31,086 (612 reported /100,000 population in SC, only MS, AL, DC had higher rates) • ~ 50 million new cases/year worldwide • Biovar: LGV • Humans are only natural host • Prevalent in Africa, Asia and South America • Sporadic in USA • 300 -500 cases/year • Male homosexuals are major reservoir

  14. Clinical Syndrome -trachoma(C.trachomatis biovar: trachoma) • Chronic or repeated infection (A - C serovar) • Follicle formation on conjunctiva • Scarring of the conjunctiva

  15. Clinical Syndrome -Trachoma • Eyelids turn in and abrade cornea • Ulceration • Scarring • Blood vessel formation

  16. Clinical Syndrome -Trachoma • Flow of tears impeded • Secondary infections occur

  17. Clinical Syndrome -Trachoma From: G. Wistreich, Microbiology Perspectives, Prentice Hall

  18. Clinical Syndrome -Trachoma

  19. Clinical Syndrome -Trachoma

  20. Clinical Syndrome - Inclusion Conjunctivitis(C. trachomatis biovar: trachoma) • Associated with genital chlamydia (Serovars D -K) • Mucopurulent discharge • Corneal infiltrates, vascularization and scarring can occur • In neonates infection results from infected birth canal • Apparent 5-12 days after birth • Ear infection and rhinitis often accompany ocular disease

  21. Clinical Syndrome - Infant Pneumonia (C. trachomatis biovar: trachoma) • Associated with genital chlamydia (serovars D - K) • Infection arises from contaminated birth canal • Wheezing cough and pneumonia but no fever • Often preceded by conjunctivitis

  22. Clinical Syndrome - Ocular Lymphogranuloma Venereum (C. trachomatis biovar: LGV) • Associated with LGV serovars (L1 - L3) • Conjunctivitis and associated lymphadenopathy (can infect macrophages)

  23. Clinical Syndrome - Urogenital Infections (C.trachomatis biovar: trachoma) • Females • Asymptomatic (80%) • Cervicitis, urethritis and salpingitis (fallopian tubes) • Postpartum fever • Increased rate • Premature delivery • Ectopic pregnancy

  24. Clinical Syndrome - Urogenital Infections (C.trachomatis biovar: trachoma) • Males • Symptomatic (75%) • Urethritis, dysuria and pyuria • Cause of nongonococcal urethritis (35 - 50%) • Common cause of postgonococcal urethritis (might have both bacteria and so both will need to be treated)

  25. Time Course of Untreated Chlamydial Urethritis in Males

  26. Clinical Syndrome - Reactive arthritis* • Conjunctivitis, polyarthritis and genital or gastrointestinal inflammation • Associated with HLA-B27 (MHC class I surface antigen associated with certain autoimmune diseases) • 50 - 65% have C. trachomatis infection • 80% have antibodies to C. trachomatis *AKA Reiter syndrome. Why replace with reactive arthritis? See Panush et al. (2007) Arthritis and Rheumatism, 56:693-694.

  27. Clinical Syndrome - Lymphogranuloma VenereumC. trachomatis (biovar: LGV) • First stage • Small painless vesicular lesion at infection site • Fever, headache and myalgia • Second stage • Inflammation of draining lymph nodes • Fever, headache and myalgia • Buboes (rupture and drain) • Proctitis • Ulcers or Elephantiasis

  28. Patient with LGV Bilateral inguinal buboes (arrows)

  29. C. trachomatis - Diagnosis Iodine-stained inclusion bodies • Cytology • Iodine-staining inclusions (glycogen) • Need tissues to see this not just pus • Not sensitive • Culture • Iodine staining inclusions • Infect cell lines • Most specific

  30. C. trachomatis - Diagnosis • Antigen detection (ELISA or IF) • Group specific LPS • Strain specific outer membrane proteins (to identify serovar) • Serology • Can’t distinguish between current or past infection • Detection of high titer IgM antibodies can be helpful to diagnose current infection • Nucleic acid probes • Several kits available • May eventually replace culture

  31. C. trachomatis - Treatment and Prevention • Tetracycline, erythromycin, and sulfonamides • Vaccines are of little value since there is no immunity with infection • Treatment coupled with improved sanitation • Safe sexual practices • Treatment of patients and their sexual partners

  32. Chlamydophila psittaci • Psittacosis (Parrot fever) • Ornithosis (since all birds can carry)

  33. Pathogenesis - C. psittaci • Inhalation of organisms in bird droppings • Person to person transmission is rare • Hematogenous spread to spleen and liver • Local necrosis of tissue • Hematogenous spread to lungs and other organs • Lymphocytic inflammatory response • Edema, infiltration of macrophages, necrosis and occasionally hemorrhage • Mucus plugs may develop in alveoli • Cyanosis and anoxia • Atypical type of pneumonia

  34. Epidemiology - C. psittaci • 50 - 100 cases per year in USA • Organisms present in birds (symptomatic or asymptomatic) • Tissue, feces, feathers • Primarily an occupational disease • Veterinarians, poultry workers, zoo keepers, pet shop workers

  35. Clinical Syndrome - OrnithosisUncomplicated Infection • Incubation period • 1-2 weeks • Fever, chills, headache, nonproductive cough, mild pneumonitis • Recovery • 5-6 weeks

  36. Clinical Syndrome - OrnithosisComplicated Infection • Incubation period • 1-2 weeks • Fever, chills, headache, nonproductive cough, mental confusion, pneumonitis, cyanosis, jaundice • Prolonged Recovery • 7-8 weeks

  37. Laboratory Diagnosis - C. psittaci • Serology (Complement fixation test) • fourfold rise in titer • requires paired samples

  38. Treatment and Prevention - C. psittaci • Tetracycline or erythromycin (sulfonamides do not work) • Quarantine of imported birds • Control of bird infection • Antibiotic supplementation of food but this may lead to resistant strains

  39. Chlamydophila pneumoniae • TWAR agent • Two isolates that ended up being identical: Taiwan (TW-183) and acute respiratory isolate (AR-39) • Atypical pneumonia • Atherosclerosis ?

  40. Pathogenesis - C. pneumoniae • Person to person spread • Respiratory droplets • Bronchitis, sinusitis, and pneumonia

  41. Epidemiology - C. pneumoniae • Common infection (200,000 - 300,000 cases per year) • Primarily in adults • Most infections are asymptomatic • Associated with crowded conditions • Schools, military bases, etc. • Association with atherosclerosis • Organisms in arterial lesions • Antibodies to C. pneumoniae

  42. Clinical Syndrome - C. pneumoniae • Mild or asymptomatic disease • Pharyngitis, bronchitis, persistent cough, and malaise • Atypical pneumonia may develop • Usually a single lobe

  43. Laboratory Diagnosis - C. pneumoniae • Serology • Fourfold rise in titer in paired samples

  44. Treatment and Prevention - C. pneumoniae • Tetracycline or erythromycin (not sulfonamides) • Difficult to prevent transmission • No vaccine

More Related